Chief Medical Officer · Arcus Biosciences, Inc. (RCUS)

Richard Markus

FY2025 is the first fiscal year CompBrief holds for Richard Markus as a named executive officer of Arcus Biosciences; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$4,506,299

2nd of 5 named executive officers at Arcus Biosciences by FY2025 total.

5 named officers on file for Arcus Biosciences, FY2025

See an example →

What this number hides

The filing gives the total. Arcus Biosciences’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed April 21, 2026 (DEF 14A).

Free

Get Richard Markus’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Richard Markus and every company like it: Velarion Intel, free for 3 days, no card →

Richard Markus compensation by year

Arcus Biosciences Summary Compensation Table · the one fiscal year held
In US dollars, as Arcus Biosciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$552,307
Bonus$100,000
Stock awards$936,153
Option awards$2,636,263
Non-equity incentive$270,000
Pension and deferred compensation$0
All other$11,576
Total$4,506,299

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Arcus Biosciences, Inc. DEF 14A filed April 21, 2026, accession 0001724521-26-000025, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Arcus Biosciences, Inc. filed document, accession 0001724521-26-000025. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU56,394$1,343,869—
Option235,357—$12.45

Per the Outstanding Equity Awards at Fiscal Year-End table in Arcus Biosciences, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Arcus Biosciences’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Terry RosenChief Executive Officer and Director$9,656,813
Richard Markus · this pageChief Medical Officer$4,506,299
Juan Carlos JaenPresident$3,520,924
Jennifer JarrettChief Operating Officer$3,516,199
Robert GoeltzChief Financial Officer$2,672,564

The full Arcus Biosciences compensation record

free company brief

This page is one person within Arcus Biosciences's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Arcus Biosciences proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Arcus Biosciences's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Arcus Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order RCUS

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Richard Markus's compensation dossier